CD79B: B-cell antigen receptor complex-associated protein beta chain
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who Is On It, and How Far Along
Every drug ChEMBL records acting on CD79B, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody-drug conjugate
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Drug | Furthest stage | Sponsor | Modality | Action | Mechanism | Open trials | Warnings |
|---|---|---|---|---|---|---|---|
| Polatuzumab vedotin | Approved | Roche | Antibody-drug conjugate | Binding agent | B-cell antigen receptor complex-associated protein beta chain binding agent | 83 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Isolated agammaglobulinemia
- 0.64
- Autosomal agammaglobulinemia
- 0.47
- Agammaglobulinemia
- 0.47
- Abnormality of the skeletal system
- 0.46
- B-cell non-Hodgkin lymphoma
- 0.45
- Neoplasm
- 0.41
- Diffuse large B-cell lymphoma of the central nervous system
- 0.39
- Primary central nervous system lymphoma
- 0.38
- Breast diffuse large B-cell lymphoma
- 0.37
- Lymphoid neoplasm
- 0.37
- Hemangioblastoma
- 0.37
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712852, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P40259, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets